<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12475139</article-id><article-id pub-id-type="pmcid-ver">PMC12475139.1</article-id><article-id pub-id-type="pmcaid">12475139</article-id><article-id pub-id-type="pmcaiid">12475139</article-id><article-id pub-id-type="pmid">41006421</article-id><article-id pub-id-type="doi">10.1038/s41598-025-14240-4</article-id><article-id pub-id-type="publisher-id">14240</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Genetic and clinical characteristics of Japanese cystinuria with exon and exon&#8211;intron boundary variants</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Sakamoto</surname><given-names initials="S">Shinichi</given-names></name><address><email>rbatbat1@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Naya</surname><given-names initials="Y">Yukio</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rii</surname><given-names initials="J">Junryo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Taguchi</surname><given-names initials="K">Kazumi</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fujimura</surname><given-names initials="M">Masaaki</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shigeta</surname><given-names initials="Y">Yasuhiro</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chairoungdua</surname><given-names initials="A">Arthit</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nishimura</surname><given-names initials="M">Motoi</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wakai</surname><given-names initials="K">Ken</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yamada</surname><given-names initials="Y">Yasutaka</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="X">Xue</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Imamura</surname><given-names initials="Y">Yusuke</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tajima</surname><given-names initials="S">Sawako</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sato</surname><given-names initials="N">Natsumi</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hosaka</surname><given-names initials="C">Chiaki</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sekine</surname><given-names initials="M">Mizuka</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ueda</surname><given-names initials="T">Takeshi</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hamamoto</surname><given-names initials="S">Shuzo</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yasui</surname><given-names initials="T">Takahiro</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kanai</surname><given-names initials="Y">Yoshikatsu</given-names></name><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Akakura</surname><given-names initials="K">Koichiro</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ikehara</surname><given-names initials="Y">Yuzuru</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Anzai</surname><given-names initials="N">Naohiko</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ichikawa</surname><given-names initials="T">Tomohiko</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01hjzeq58</institution-id><institution-id institution-id-type="GRID">grid.136304.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0370 1101</institution-id><institution>Department of Urology, </institution><institution>Chiba University Graduate School of Medicine, </institution></institution-wrap> 1-8-1 Inohana, Chuo ku, Chiba, Chiba, 260-8670 Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03edth057</institution-id><institution-id institution-id-type="GRID">grid.412406.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0467 0888</institution-id><institution>Department of Urology, </institution><institution>Teikyo University Chiba Medical Center, </institution></institution-wrap>Ichihara, Japan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04wn7wc95</institution-id><institution-id institution-id-type="GRID">grid.260433.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0728 1069</institution-id><institution>Department of Nephro-Urology, </institution><institution>Nagoya City University Graduate School of Medical Sciences, </institution></institution-wrap>Nagoya, Japan </aff><aff id="Aff4"><label>4</label>Department of Urology, Saiseikai Narashino Hospital, Narashino, Japan </aff><aff id="Aff5"><label>5</label>Nishi Funabashi Urology Clinic, Funabashi, Japan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01znkr924</institution-id><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution>Department of Physiology, Faculty of Science, </institution><institution>Mahidol University, </institution></institution-wrap>Salaya, Thailand </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0126xah18</institution-id><institution-id institution-id-type="GRID">grid.411321.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0632 2959</institution-id><institution>Division of Clinical Genetics, </institution><institution>Chiba University Hospital, </institution></institution-wrap>Chiba, Japan </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/012e6rh19</institution-id><institution-id institution-id-type="GRID">grid.412781.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1775 2495</institution-id><institution>Clinical Genetics Center, </institution><institution>Tokyo Medical University Hospital, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff9"><label>9</label>Nagaura Urology Clinic, Sodegaura, Japan </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/035t8zc32</institution-id><institution-id institution-id-type="GRID">grid.136593.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0373 3971</institution-id><institution>Department of Bio-System Pharmacology, Graduate School of Medicine, </institution><institution>Osaka University, </institution></institution-wrap>Suita, Japan </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/035t8zc32</institution-id><institution-id institution-id-type="GRID">grid.136593.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0373 3971</institution-id><institution>Department of Metabolic Reprograming and Signal Regulation, Premium Research Institute for Human Metaverse Medicine (WPI-PRIMe), </institution><institution>Osaka University, </institution></institution-wrap>Suita, Japan </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/046f6cx68</institution-id><institution-id institution-id-type="GRID">grid.256115.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 1761 798X</institution-id><institution>Center for Society-Academia Collaboration, Research Promotion Headquarters, </institution><institution>Fujita Health University, </institution></institution-wrap>Toyoake, Japan </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03q11y497</institution-id><institution-id institution-id-type="GRID">grid.460248.c</institution-id><institution>Department of Urology, </institution><institution>Japan Community Healthcare Organization (JCHO) Mishima General Hospital, </institution></institution-wrap>Shizuoka, Japan </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01hjzeq58</institution-id><institution-id institution-id-type="GRID">grid.136304.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0370 1101</institution-id><institution>Department of Tumor Pathology, </institution><institution>Chiba University Graduate School of Medicine, </institution></institution-wrap>Chiba, Japan </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01hjzeq58</institution-id><institution-id institution-id-type="GRID">grid.136304.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0370 1101</institution-id><institution>Department of Pharmacology, </institution><institution>Chiba University Graduate School of Medicine, </institution></institution-wrap>Chiba, Japan </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>33066</elocation-id><history><date date-type="received"><day>10</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>30</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 16:25:18.507"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2025_Article_14240.pdf"/><abstract id="Abs1"><p id="Par1">Cystinuria is the most common genetic cause of urinary stones. Defects in <italic toggle="yes">SLC3A1</italic>/<italic toggle="yes">SLC7A9</italic> genes coding cystine transporter proteins rBAT/b<sup>0,+</sup>AT will cause Cystinuria. The current work analyzed the clinical and genetic characteristics of Japanese Cystinuria patients. In total, 101 Cystinuria patients were studied. Clinical phenotypes were defined, and genetic analysis of <italic toggle="yes">SLC3A1</italic> and <italic toggle="yes">SLC7A9</italic> was performed by next-generation sequencing. Excretion of cystine was determined by 24&#160;h urine analysis. The median age of presentation was 17&#160;years. In total, 51 different mutant variant alleles were identified (22 and 29 mutant variants in <italic toggle="yes">SLC3A1</italic> and <italic toggle="yes">SLC7A9</italic>, respectively), including 25 novel variants. The p.(Pro482Leu) (c.1445C&#8201;&gt;&#8201;T) variant in <italic toggle="yes">SCL7A9</italic> was predominantly found in 73 patients. Variants in exon&#8211;intron boundaries were identified in 6 cases. The patient with a homozygote intron (exon&#8211;intron boundary) variant in <italic toggle="yes">SCL7A9</italic> presented a severe phenotype with a significant loss of mRNA expression. Including exon and exon&#8211;intron boundary variants reduced the number of cases that did not fit autosomal recessive inheritance from 14 to 9%. Current data revealed a specific genotype of Japanese cystinuria through the analysis of exon and exon&#8211;intron boundaries.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cystinuria</kwd><kwd>Urinary stone</kwd><kwd>Genetic variant</kwd><kwd>Germline variant</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Genetic variation</kwd><kwd>Renal calculi</kwd><kwd>Genetics</kwd><kwd>Nephrology</kwd><kwd>Urology</kwd></kwd-group><funding-group><award-group><funding-source><institution>5th research grant from Japanese Society on Urolithiasis Research to S. Sakamoto</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>The Initiative on Rare and Undiagnosed Diseases (IRUD) to T. Ichikawa</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>The Japan Agency for Medical Research and Development (AMED) &#65288;JP21ek0109549&#65289;to T. Ichikawa</institution></funding-source><award-id>JP21ek0109549</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Cystinuria (OMIM 220100) is a most common inherited urinary stone disease found in 1&#8211;2% of overall kidney stones. In the general population, the prevalence of cystinuria was reported to be 1/7000 to 1/50000<sup><xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref></sup>. Although the prevalence rate of cystinuria is low, the affected patients will suffer recurrent urinary stones from childhood and may undergo a series of surgeries, which will damage renal function and quality of life. It is essential to obtain the diagnosis at an early age and early stage of urinary stones.</p><p id="Par3">Cystinuria is caused by a pathogenic variants in two genes; <italic toggle="yes">SLC3A1</italic> (OMIM 104614) encodes an rBAT (a single transmembrane protein), and <italic toggle="yes">SLC7A9</italic> (OMIM 604144) encodes b<sup>0,+</sup>AT (a twelve transmembrane protein)<sup><xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref></sup>. rBAT and b<sup>0,+</sup>AT form a dimer linked by a disulfide bond to form the heterodimeric structure of transporter. B<sup>0,+</sup>AT form the channel which transports dibasic amino acids (cystine, lysine, arginine, and ornithine) into the cell with the exchange of neutral amino acids. rBAT contains the multiple glycosylation sites at the extracellular domain. Interaction of b<sup>0,+</sup>AT is required for the rBAT to be fully glycosylated and properly folded and stably expressed at the apical membrane of proximal tubule<sup><xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref></sup>. We have reported the role of carboxyl-terminal of b<sup>0,+</sup>AT in controlling the trafficking of the rBAT-b<sup>0,+</sup>AT from the endoplasmic reticulum (ER) to Golgi complex and thus control the full glycosylation of the rBAT protein<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>.</p><p id="Par4">Strologo et al. proposed the genome-based cystinuria classification<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. The genotypes were classified, such as type A, due to two variants of <italic toggle="yes">SLC3A1</italic>; type B, due to two variants of <italic toggle="yes">SLC7A9</italic>; and type AB, with one variant on each of the above-mentioned genes. However, Rhodes et al. reported that over thirty percent of the cystinuria patients in the United Kingdom only possessed a single variant or even no variant, who will not fit into the genotypes previously proposed which will fit into the autosomal recessive inheritance<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>. Thus, it is of need to establish the genomic classification which will cover the unfit cases of genotype in cystinuria.</p><p id="Par5">Previously, we have been studied Japanese cystinuria since 1980&#8217;s and in 2006, we identified the presence of a unique variant; p.(Pro482Leu), is located at the carboxyl terminus end of B<sup>0,+</sup>AT among Japanese cystinuria patients<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR17">17</xref></sup>. The p.(Pro482Leu) variant caused a severe functional defect of the cystine transporter, which was found in over 80% of Japanese cystinuria patients<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. The high prevalence of the p.(Pro482Leu) variant had never been reported elsewhere. The prevalence of p.(Pro482Leu) variant among cystinuria patients was reported 1/8 in South Korea<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>, 1/73 in the United Kingdom<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>, while no report in China<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Because of a distinct genotype in Japanese cystinuria patients, a distinct clinical feature was also expected.</p><p id="Par6">Our previous genetic study of cystinuria was based on exon lesion with sanger sequence. However, in recent years, a number of effects of the exon intron boundary on mRNA splicing have been reported<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. And also, there may be a variant that could be missed by the sanger sequence. In order to precisely understand the genomic feature of Japanese cystinuria, here we studied the genomic characteristics of 101 Japanese cystinuria patients by next generation sequencing including exon&#8211;intron boundaries.</p></sec><sec id="Sec2"><title>Results</title><sec id="Sec3"><title>Clinical features</title><p id="Par7">In total, 101 patients diagnosed with cystinuria were identified comprising 36 (35.6%) women and 65 (64.4%) men. All patients were Japanese. A positive family history of cystinuria was documented in 29 (28.7%) of patients; 19 (18.8%) patients had only one generation affected (siblings), 10 (9.9%) patients had two generations affected. The median age at first presentation of stone symptom was 17&#160;years old (range&#8201;=&#8201;0&#8211;58&#160;years old) with a median age of 17.0&#160;years old in the male and 16.5&#160;years old in the female. The proportion of onset age for less than ten years, teenage, the 20&#160;s and 30&#160;s, and over were 38%, 24%, 25%, and 13%, respectively (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Demographic and clinical data.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Characteristic</th><th align="left" colspan="1" rowspan="1">Value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Number of patients (N)</td><td align="left" colspan="1" rowspan="1">101</td></tr><tr><td align="left" colspan="1" rowspan="1">Median age at presentation (years) (range)</td><td align="left" colspan="1" rowspan="1">17.0 (0&#8211;58)</td></tr><tr><td align="left" colspan="1" rowspan="1">Less than 10&#160;years/teen age/20&#160;s/30&#160;s and over</td><td align="left" colspan="1" rowspan="1">38/24/25/13(%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">17.0 (0&#8211;48)</td></tr><tr><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">16.5 (0&#8211;58)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sex</td><td align="left" colspan="1" rowspan="1">male (N&#8201;=&#8201;65)/ female (N&#8201;=&#8201;36)</td></tr><tr><td align="left" colspan="1" rowspan="1">Family Histroy (1st sibling/2nd sibling)</td><td align="left" colspan="1" rowspan="1">29% (19%/10%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ethnicity: Japanese</td><td align="left" colspan="1" rowspan="1">100%</td></tr><tr><td align="left" colspan="1" rowspan="1">Median age at follow-up (years)</td><td align="left" colspan="1" rowspan="1">33.0 (0.3&#8211;78.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Median time from initial symptoms to follow-up (years)</td><td align="left" colspan="1" rowspan="1">14.0 (0.0&#8211;56.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Cystine (&#956;mol/day)</td><td align="left" colspan="1" rowspan="1">1745.7 (184.6&#8212;5303.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ornithine (&#956;mol/day)</td><td align="left" colspan="1" rowspan="1">2044.3 (205.2&#8212;7471.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Lysine (&#956;mol/day)</td><td align="left" colspan="1" rowspan="1">8646.7 (536.9&#8212;36961.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Arginine (&#956;mol/day)</td><td align="left" colspan="1" rowspan="1">3334.2 (96.3&#8212;12096.0)</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>Genetic analysis</title><p id="Par8">Genetic analysis was performed in all 101patients. At least two distinct genetic variants were detected in 93 patients (53 patients were homozygote and 40 patients were compound heterozygote), while 8 patients only had a single variant. All the patients had at least one variant. Variants in <italic toggle="yes">SLC3A1</italic> were identified in 18 patients, and variants in <italic toggle="yes">SLC7A9</italic> were identified in 88 patients. Variants in both <italic toggle="yes">SLC3A1</italic> and <italic toggle="yes">SLC7A9</italic> were identified in 5 patients.</p><p id="Par9">Overall, 51 distinct variants were identified in <italic toggle="yes">SLC3A1</italic> and <italic toggle="yes">SLC7A9</italic> (Tables <xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref>). Among 22 variants identified in <italic toggle="yes">SLC3A1</italic>, 13 variants were unreported (novel) variant (Table <xref rid="Tab2" ref-type="table">2</xref>). Among 29 variants identified in <italic toggle="yes">SLC7A9</italic>, 12 variants were unreported (novel) variants (Table <xref rid="Tab3" ref-type="table">3</xref>). In <italic toggle="yes">SLC3A1</italic>, 13 missense variants were identified, followed by four frameshifts and two splice-site variants, and one nonsense variant (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>A). The most frequent variant in <italic toggle="yes">SLC3A1</italic> was p.(Val83Ala) (c.5487T&#8201;&gt;&#8201;C), which was found in 3 patients (3.0%), followed by exon 10 deletion and p.Asn442fs. (c.1323dupT), which were found in 2 patients (2.0%) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>A, Table <xref rid="Tab2" ref-type="table">2</xref>). In <italic toggle="yes">SLC7A9</italic>, 24 missense variants were identified, followed by three splice site and frameshift variants. One nonsense and one initial codon variant were also found (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>B).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>List of variants in <italic toggle="yes">SLC3A1.</italic></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">SLC3A1</th><th align="left" colspan="1" rowspan="1">Variant type</th><th align="left" colspan="1" rowspan="1">Variants</th><th align="left" colspan="1" rowspan="1">Protein sequence</th><th align="left" colspan="1" rowspan="1">Homo/Hetero</th><th align="left" colspan="1" rowspan="1">Number</th><th align="left" colspan="1" rowspan="1">Exon</th><th align="left" colspan="1" rowspan="1">Location</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.283G&#8201;&gt;&#8201;A*</td><td align="left" colspan="1" rowspan="1">p.(Ala95Thr)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">TM1</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.313A&#8201;&gt;&#8201;G*</td><td align="left" colspan="1" rowspan="1">p.(Ile105Val)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">TM1</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.470&#160;T&#8201;&gt;&#8201;C*</td><td align="left" colspan="1" rowspan="1">p.(Ile157Thr)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Extra</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.548&#160;T&#8201;&gt;&#8201;C*</td><td align="left" colspan="1" rowspan="1">p.(Val183Ala)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Extra</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.659A&#8201;&gt;&#8201;G*</td><td align="left" colspan="1" rowspan="1">p.(His220Arg)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Extra</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.763&#160;T&#8201;&gt;&#8201;A *</td><td align="left" colspan="1" rowspan="1">p.(Trp255Arg)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Extra</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.989A&#8201;&gt;&#8201;C*</td><td align="left" colspan="1" rowspan="1">p.(Gln330Pro)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Extra</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.1037&#160;T&#8201;&gt;&#8201;C</td><td align="left" colspan="1" rowspan="1">p.(Leu346Pro)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Extra</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.1323C&#8201;&gt;&#8201;G*</td><td align="left" colspan="1" rowspan="1">p.(Pro441Arg)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Extra</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.1334&#160;T&#8201;&gt;&#8201;C</td><td align="left" colspan="1" rowspan="1">p.(Ile445Thr)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">Extra</td></tr><tr><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.1742&#160;T&#8201;&gt;&#8201;G*</td><td align="left" colspan="1" rowspan="1">p.(Val581Gly)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Extra</td></tr><tr><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.1772G&#8201;&gt;&#8201;A *</td><td align="left" colspan="1" rowspan="1">p.(Arg591Lys)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Extra</td></tr><tr><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.2017&#160;T&#8201;&gt;&#8201;C</td><td align="left" colspan="1" rowspan="1">p.(Cys673Arg)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Extra</td></tr><tr><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">Nonsense</td><td align="left" colspan="1" rowspan="1">c.1113C&#8201;&gt;&#8201;A</td><td align="left" colspan="1" rowspan="1">p.(Tyr371X)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Extra</td></tr><tr><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">Nonsense</td><td align="left" colspan="1" rowspan="1">c.1328G&#8201;&gt;&#8201;A*</td><td align="left" colspan="1" rowspan="1">p.(Trp443X)</td><td align="left" colspan="1" rowspan="1">Homo</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Extra</td></tr><tr><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">Frameshift</td><td align="left" colspan="1" rowspan="1">c.1323dupT*</td><td align="left" colspan="1" rowspan="1">p.(Asn442fs)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Extra</td></tr><tr><td align="left" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1">Frameshift</td><td align="left" colspan="1" rowspan="1">c.1820delT</td><td align="left" colspan="1" rowspan="1">p.(Leu607fs)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Extra</td></tr><tr><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">Frameshift</td><td align="left" colspan="1" rowspan="1">c.1820delT</td><td align="left" colspan="1" rowspan="1">p.(Leu607fs)</td><td align="left" colspan="1" rowspan="1">Homo</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Extra</td></tr><tr><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">Frameshift</td><td align="left" colspan="1" rowspan="1">c.1898_1899insAT</td><td align="left" colspan="1" rowspan="1">p.(Asp634fs)</td><td align="left" colspan="1" rowspan="1">Homo</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Extra</td></tr><tr><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">Splice site</td><td align="left" colspan="1" rowspan="1">c.1500&#8201;+&#8201;1G&#8201;&gt;&#8201;A</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">8&#8201;+&#8201;1 intro</td><td align="left" colspan="1" rowspan="1">Extra</td></tr><tr><td align="left" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">Splice site</td><td align="left" colspan="1" rowspan="1">c.1617&#8201;+&#8201;1_1617&#8201;+&#8201;2dupGT*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">9&#8201;+&#8201;1&#8201;+&#8201;2 intron</td><td align="left" colspan="1" rowspan="1">Extra</td></tr><tr><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">Deletions</td><td align="left" colspan="1" rowspan="1">Ex10 deletion</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Homo</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Extra</td></tr></tbody></table><table-wrap-foot><p>Missense: missense variant, Frameshift: frame shift variant, Nonsense: nonsense variant, Splice site: splice site variant (exon&#8211;intron boundary variant), TM: transmembrane domain, Extra: extracellular domain, *: novel variant not reported previously. These gene variants are described with reference to the sequence of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000341.3">NM_000341.3</ext-link>.</p></table-wrap-foot></table-wrap><table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>List of variants in<italic toggle="yes"> SLC7A9.</italic></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">SLC7A9</th><th align="left" colspan="1" rowspan="1">Variant type</th><th align="left" colspan="1" rowspan="1">Variants</th><th align="left" colspan="1" rowspan="1">Protein sequence</th><th align="left" colspan="1" rowspan="1">Homo/Hetero</th><th align="left" colspan="1" rowspan="1">Number</th><th align="left" colspan="1" rowspan="1">Exon</th><th align="left" colspan="1" rowspan="1">Location</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Initial codon variant</td><td align="left" colspan="1" rowspan="1">c.2T&#8201;&gt;&#8201;C*</td><td align="left" colspan="1" rowspan="1">p.(Met1Thr)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Cytoplasmic</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Nonesense</td><td align="left" colspan="1" rowspan="1">c.206G&#8201;&gt;&#8201;A</td><td align="left" colspan="1" rowspan="1">p.(Trp69X)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">TM2</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.209C&#8201;&gt;&#8201;T</td><td align="left" colspan="1" rowspan="1">p.(Ala70Val)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">TM2</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.217G&#8201;&gt;&#8201;A</td><td align="left" colspan="1" rowspan="1">p.(Gly73Arg)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">TM2</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.308C&#8201;&gt;&#8201;T*</td><td align="left" colspan="1" rowspan="1">p.(Ala103Val)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">TM3</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.511C&#8201;&gt;&#8201;T</td><td align="left" colspan="1" rowspan="1">p.(Arg171Trp)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Cytoplasmic Loop2</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.583G&#8201;&gt;&#8201;A</td><td align="left" colspan="1" rowspan="1">p.(Gly195Arg)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">TM5</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.650C&#8201;&gt;&#8201;G*</td><td align="left" colspan="1" rowspan="1">p.(Ser217Cys)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">TM6</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.671C&#8201;&gt;&#8201;T</td><td align="left" colspan="1" rowspan="1">p.(Ala224Val)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">TM6</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.679A&#8201;&gt;&#8201;G</td><td align="left" colspan="1" rowspan="1">p.(Asn227Asp)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">TM6</td></tr><tr><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.698A&#8201;&gt;&#8201;G*</td><td align="left" colspan="1" rowspan="1">p.(Asp233Gly)</td><td align="left" colspan="1" rowspan="1">Homo/Hetero</td><td align="left" colspan="1" rowspan="1">1/1</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Cytoplasmic Loop3</td></tr><tr><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.829G&#8201;&gt;&#8201;A</td><td align="left" colspan="1" rowspan="1">p.(Val277Met)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Extra Loop4</td></tr><tr><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.886C&#8201;&gt;&#8201;G*</td><td align="left" colspan="1" rowspan="1">p.(Arg296Gly)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Extra Loop4</td></tr><tr><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.968C&#8201;&gt;&#8201;T*</td><td align="left" colspan="1" rowspan="1">p.(Thr323Ile)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Cytoplasmic Loop4</td></tr><tr><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.974G&#8201;&gt;&#8201;T*</td><td align="left" colspan="1" rowspan="1">p.(Gly325Val)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Cytoplasmic Loop4</td></tr><tr><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.992C&#8201;&gt;&#8201;T</td><td align="left" colspan="1" rowspan="1">p.(Ala331Val)</td><td align="left" colspan="1" rowspan="1">Homo</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Cytoplasmic Loop4</td></tr><tr><td align="left" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.998G&#8201;&gt;&#8201;A</td><td align="left" colspan="1" rowspan="1">p.(Arg333Gln)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Cytoplasmic Loop4</td></tr><tr><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.1060G&#8201;&gt;&#8201;A</td><td align="left" colspan="1" rowspan="1">p.(Ala354Thr)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">TM9</td></tr><tr><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.1061C&#8201;&gt;&#8201;A</td><td align="left" colspan="1" rowspan="1">p.(Ala354Asp)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">TM9</td></tr><tr><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.1124T&#8201;&gt;&#8201;C*</td><td align="left" colspan="1" rowspan="1">p.(Val375Ala)</td><td align="left" colspan="1" rowspan="1">Homo</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">TM10</td></tr><tr><td align="left" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.1166C&#8201;&gt;&#8201;T</td><td align="left" colspan="1" rowspan="1">p.(Thr389Met)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">TM10</td></tr><tr><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.1336A&#8201;&gt;&#8201;C*</td><td align="left" colspan="1" rowspan="1">p.(Ser446Arg)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">TM12</td></tr><tr><td align="left" colspan="1" rowspan="1">23</td><td align="left" colspan="1" rowspan="1">Missense</td><td align="left" colspan="1" rowspan="1">c.1445C&#8201;&gt;&#8201;T</td><td align="left" colspan="1" rowspan="1">p.(Pro482Leu)</td><td align="left" colspan="1" rowspan="1">Homo/Hetero</td><td align="left" colspan="1" rowspan="1">43/30</td><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">Cytoplasmic</td></tr><tr><td align="left" colspan="1" rowspan="1">24</td><td align="left" colspan="1" rowspan="1">Frameshift</td><td align="left" colspan="1" rowspan="1">c.611_612delCA</td><td align="left" colspan="1" rowspan="1">p.(Thr204fs)</td><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Extra Loop3</td></tr><tr><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">Frameshift</td><td align="left" colspan="1" rowspan="1">c.1017delA</td><td align="left" colspan="1" rowspan="1">p.(Val340fs)</td><td align="left" colspan="1" rowspan="1">Homo/Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Cytoplasmic Loop4</td></tr><tr><td align="left" colspan="1" rowspan="1">26</td><td align="left" colspan="1" rowspan="1">Splice site</td><td align="left" colspan="1" rowspan="1">c.873&#8201;+&#8201;2dupT*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Intron(Exon 8&#8201;+&#8201;2)</td><td align="left" colspan="1" rowspan="1">Extra Loop4</td></tr><tr><td align="left" colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">Splice site</td><td align="left" colspan="1" rowspan="1">c.1074&#8201;+&#8201;1G&#8201;&gt;&#8201;A*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Intron(Exon 10&#8201;+&#8201;1)</td><td align="left" colspan="1" rowspan="1">Extra Loop5</td></tr><tr><td align="left" colspan="1" rowspan="1">28</td><td align="left" colspan="1" rowspan="1">Splice site</td><td align="left" colspan="1" rowspan="1">c.1224&#8201;+&#8201;3A&#8201;&gt;&#8201;C*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Homo</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Intron(Exon 11&#8201;+&#8201;3)</td><td align="left" colspan="1" rowspan="1">Cytoplasmic Loop5</td></tr><tr><td align="left" colspan="1" rowspan="1">29</td><td align="left" colspan="1" rowspan="1">Splice site</td><td align="left" colspan="1" rowspan="1">c.1399&#8201;+&#8201;4_1399&#8201;+&#8201;7delAGTA</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Hetero</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Intron(Exon 12&#8201;+&#8201;4&#8211;7)</td><td align="left" colspan="1" rowspan="1">TM12</td></tr></tbody></table><table-wrap-foot><p>Missense: missense variant, Frameshift: frame shift variant, Nonsense: nonsense variant, Splice site: splice site variant (exon&#8211;intron boundary variant), TM: transmembrane domain, *: novel variant not reported previously. These gene variants are described with reference to the sequence of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001126335.1">NM_001126335.1</ext-link>.</p></table-wrap-foot></table-wrap><fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Distribution of variant in SLC<italic toggle="yes">3A1</italic> and SCL7A9. In <italic toggle="yes">SLC3A1</italic>, 13 missense variants were identified, followed by 4 frameshifts and 2 splice-site variants, and 1 nonsense variant. The most frequent variant in <italic toggle="yes">SLC3A1</italic> was p.(Val183Ala) (c.5487T&#8201;&gt;&#8201;C), followed by Exon 10 deletion and p.Asn442fs. (c.1323dupT). In <italic toggle="yes">SLC7A9</italic>, 20 missense variants were identified, followed by 4 splice site and 2 frameshift variants were identified. One nonsense and 1 initial codon variant were also found. The most frequent variant in <italic toggle="yes">SLC7A9</italic> was p.(Pro482Leu) (c.1445C&#8201;&gt;&#8201;T), which was found in 73 patients (43 homozygous and 30 heterozygous). Red column indicated novel variant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="41598_2025_14240_Fig1_HTML.jpg"/></fig></p><p id="Par10">The most frequent variant in <italic toggle="yes">SLC7A9</italic> was p.(Pro482Leu) (c.1445C&#8201;&gt;&#8201;T), which was found in 73 patients (72.7%)(43 homozygous and 30 heterozygous), followed by p.Val340fs (c.1017delA), which was found in 9 patients (8.9%)(1 homozygous and eight heterozygous) and p.(Asn227Asp) (c.679A&#8201;&gt;&#8201;G), which was found in 4 patients (4.0%)(4 heterozygous) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>B, Table <xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec5"><title>Location of variants</title><p id="Par11">Regarding the location of the variants, all the variants in <italic toggle="yes">SLC3A1</italic> were located at the extracellular domain except for p.Ala95Thr (c.313A&#8201;&gt;&#8201;G) and p.Ile105Val (c.313A&#8201;&gt;&#8201;G), which were located in the transmembrane domain of rBAT (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A). For the <italic toggle="yes">SLC7A9</italic>, the most common variant, p.(Pro482Leu), was located at the carboxyl terminus, while p.(Met1Thr) (c.2T&#8201;&gt;&#8201;C) was located in the N-terminus of b<sup>0,+</sup>AT. Other variants were located at either transmembrane domain (14 variants), cytoplasmic loop (8 variants), or extracellular loop (5 variants) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Location of variants in rBAT (<italic toggle="yes">SLC3A1</italic>) and b<sup>0,+</sup>AT (<italic toggle="yes">SLC7A9</italic>) in exon and protein domain. Schematic diagram of rBAT and b<sup>0,+</sup>AT. rBAT protein has a single transmembrane domain (Blue) with a long extracellular domain with cytoplasmic domain encoded by ten exons (<bold>A</bold>). b<sup>0,+</sup>AT protein has 12 transmembrane domains with a cytoplasmic domain at N-terminus and C-terminus. p.(Pro482Leu) variant is located at the C-terminus end (<bold>B</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="41598_2025_14240_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec6"><title>Genome-phenotype association</title><p id="Par12">Amount of urine cystine for the patients who have variant in <italic toggle="yes">SLC3A1</italic>, <italic toggle="yes">SCL7A9</italic> and <italic toggle="yes">SLC3A1/SLC7A9</italic> were 1357.15, 1815.45 and 1434&#160;&#181;&#160;mol/day, respectively (Table <xref rid="Tab4" ref-type="table">4</xref>). Regarding genotype, 12 patients (11.9%) were type AA and 76 patients (75.2%) were type BB, while 1 patient (1.0%) was type AAB, 4 patients (4.0%) were type ABB, 1 patient (1.0%) was type A and 7 patients (6.9%) were type B (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A).<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Aminoacid concentration based on Genes, Genotype and p.(Pro482Leu) variant.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="9" rowspan="1"><italic toggle="yes">Urine Amino acids: &#181;mol/day</italic></th></tr><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Cystine</th><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Ornithine</th><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Lysine</th><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Arginine</th><th align="left" colspan="1" rowspan="1"/></tr><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Median</th><th align="left" colspan="1" rowspan="1">Range</th><th align="left" colspan="1" rowspan="1">Median</th><th align="left" colspan="1" rowspan="1">Range</th><th align="left" colspan="1" rowspan="1">Median</th><th align="left" colspan="1" rowspan="1">Range</th><th align="left" colspan="1" rowspan="1">Median</th><th align="left" colspan="1" rowspan="1">Range</th></tr></thead><tbody><tr><td align="left" colspan="9" rowspan="1"><italic toggle="yes">Based on genes</italic></td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">SLC3A1</italic></td><td align="left" colspan="1" rowspan="1">1357.2</td><td align="left" colspan="1" rowspan="1">(186.9&#8211;3117.9)</td><td align="left" colspan="1" rowspan="1">1692.6</td><td align="left" colspan="1" rowspan="1">(861.3&#8211;3848.1)</td><td align="left" colspan="1" rowspan="1">7051.8</td><td align="left" colspan="1" rowspan="1">(5307.9&#8211;12456.4)</td><td align="left" colspan="1" rowspan="1">2682.7</td><td align="left" colspan="1" rowspan="1">(323.4&#8211;4590.5)</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">SLC7A9</italic></td><td align="left" colspan="1" rowspan="1">1832.2</td><td align="left" colspan="1" rowspan="1">(184.6&#8211;5303.4)</td><td align="left" colspan="1" rowspan="1">2020.15</td><td align="left" colspan="1" rowspan="1">(205.2&#8211;7471.7)</td><td align="left" colspan="1" rowspan="1">8787.8</td><td align="left" colspan="1" rowspan="1">(536.9&#8211;36961.6)</td><td align="left" colspan="1" rowspan="1">3334.2</td><td align="left" colspan="1" rowspan="1">(96.3&#8211;12096)</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">SLC3A1/SLC7A9</italic></td><td align="left" colspan="1" rowspan="1">1434</td><td align="left" colspan="1" rowspan="1">(1037.3&#8211;3722.9)</td><td align="left" colspan="1" rowspan="1">3174.4</td><td align="left" colspan="1" rowspan="1">(2302.1&#8211;4316.8)</td><td align="left" colspan="1" rowspan="1">8144</td><td align="left" colspan="1" rowspan="1">(1300.2&#8211;13826.2)</td><td align="left" colspan="1" rowspan="1">3495.9</td><td align="left" colspan="1" rowspan="1">(2269&#8211;5996.8)</td></tr><tr><td align="left" colspan="9" rowspan="1"><italic toggle="yes">Based on genotype</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">AA</td><td align="left" colspan="1" rowspan="1">1230.6</td><td align="left" colspan="1" rowspan="1">(186.9&#8211;3117.9)</td><td align="left" colspan="1" rowspan="1">1355.8</td><td align="left" colspan="1" rowspan="1">(861.3&#8211;3848.1)</td><td align="left" colspan="1" rowspan="1">5631.6</td><td align="left" colspan="1" rowspan="1">(5307.9&#8211;9223.1)</td><td align="left" colspan="1" rowspan="1">1002.9</td><td align="left" colspan="1" rowspan="1">(323.4&#8211;4590.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">BB</td><td align="left" colspan="1" rowspan="1">1815.45</td><td align="left" colspan="1" rowspan="1">(184.6&#8211;5303.4)</td><td align="left" colspan="1" rowspan="1">2036.8</td><td align="left" colspan="1" rowspan="1">(205.2&#8211;7417.7)</td><td align="left" colspan="1" rowspan="1">8858.5</td><td align="left" colspan="1" rowspan="1">(536.9&#8211;36,961.6)</td><td align="left" colspan="1" rowspan="1">3334.2</td><td align="left" colspan="1" rowspan="1">(150.4&#8211;12096)</td></tr><tr><td align="left" colspan="1" rowspan="1">AAB/BBA</td><td align="left" colspan="1" rowspan="1">1434</td><td align="left" colspan="1" rowspan="1">(1037.3&#8211;3722.9)</td><td align="left" colspan="1" rowspan="1">3174.4</td><td align="left" colspan="1" rowspan="1">(2302.1&#8211;4316.8)</td><td align="left" colspan="1" rowspan="1">8144</td><td align="left" colspan="1" rowspan="1">(1300.2&#8211;13826.2)</td><td align="left" colspan="1" rowspan="1">3495.9</td><td align="left" colspan="1" rowspan="1">(2269&#8211;5996.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">A</td><td align="left" colspan="1" rowspan="1">3034.6</td><td align="left" colspan="1" rowspan="1">(3034.6&#8211;3034.6)</td><td align="left" colspan="1" rowspan="1">2029.4</td><td align="left" colspan="1" rowspan="1">(2029.4&#8211;2029.4)</td><td align="left" colspan="1" rowspan="1">12,456.4</td><td align="left" colspan="1" rowspan="1">(12456.5&#8211;12456.5)</td><td align="left" colspan="1" rowspan="1">4425.4</td><td align="left" colspan="1" rowspan="1">(4425.4&#8211;4425.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">B</td><td align="left" colspan="1" rowspan="1">1968.8</td><td align="left" colspan="1" rowspan="1">(592.8&#8211;4094.2)</td><td align="left" colspan="1" rowspan="1">1616.4</td><td align="left" colspan="1" rowspan="1">(278.3&#8211;2843)</td><td align="left" colspan="1" rowspan="1">8576.3</td><td align="left" colspan="1" rowspan="1">(3038.4&#8211;10211.1)</td><td align="left" colspan="1" rowspan="1">555.9</td><td align="left" colspan="1" rowspan="1">(96.3&#8211;5037.6)</td></tr><tr><td align="left" colspan="9" rowspan="1"><italic toggle="yes">Based on p.(Pro482Leu)</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">p.(Pro482Leu) Homo</td><td align="left" colspan="1" rowspan="1">1705.15</td><td align="left" colspan="1" rowspan="1">(184.6&#8211;4368)</td><td align="left" colspan="1" rowspan="1">2195.6</td><td align="left" colspan="1" rowspan="1">(205.2&#8211;4316.8)</td><td align="left" colspan="1" rowspan="1">8858.5</td><td align="left" colspan="1" rowspan="1">(536.9&#8211;17412)</td><td align="left" colspan="1" rowspan="1">3423.4</td><td align="left" colspan="1" rowspan="1">(150.4&#8211;6531)</td></tr><tr><td align="left" colspan="1" rowspan="1">p.(Pro482Leu) compound hetero</td><td align="left" colspan="1" rowspan="1">2359.3</td><td align="left" colspan="1" rowspan="1">(851&#8211;5303.4)</td><td align="left" colspan="1" rowspan="1">2183.1</td><td align="left" colspan="1" rowspan="1">(716&#8211;7471.7)</td><td align="left" colspan="1" rowspan="1">8970.1</td><td align="left" colspan="1" rowspan="1">(2968.4&#8211;36961.6)</td><td align="left" colspan="1" rowspan="1">3875.3</td><td align="left" colspan="1" rowspan="1">(1416.6&#8211;12096)</td></tr><tr><td align="left" colspan="1" rowspan="1">p.(Pro482Leu) single Hetero</td><td align="left" colspan="1" rowspan="1">1280.8</td><td align="left" colspan="1" rowspan="1">(592.8&#8211;1968.8)</td><td align="left" colspan="1" rowspan="1">1560.65</td><td align="left" colspan="1" rowspan="1">(278.3&#8211;2843)</td><td align="left" colspan="1" rowspan="1">5807.4</td><td align="left" colspan="1" rowspan="1">(3038.4&#8211;8576.3)</td><td align="left" colspan="1" rowspan="1">2567</td><td align="left" colspan="1" rowspan="1">(96.3&#8211;5037.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">None p.(Pro482Leu)</td><td align="left" colspan="1" rowspan="1">1483.7</td><td align="left" colspan="1" rowspan="1">(186.9&#8211;4094.2)</td><td align="left" colspan="1" rowspan="1">1822.9</td><td align="left" colspan="1" rowspan="1">(845.4&#8211;5497.2)</td><td align="left" colspan="1" rowspan="1">8594.5</td><td align="left" colspan="1" rowspan="1">(2411.5&#8211;16476.1)</td><td align="left" colspan="1" rowspan="1">1729.4</td><td align="left" colspan="1" rowspan="1">(323.4&#8211;9512.9)</td></tr></tbody></table></table-wrap><fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Distribution of cystinuria genotype. Distribution of genotype represented predominance of type BB followed by type AA and type B (<bold>A</bold>). Urine cystine based on the genotype (<bold>B</bold>). Age of onset based on the genotype (<bold>C</bold>)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="41598_2025_14240_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec7"><title>Genotype&#8211;phenotype association</title><p id="Par13">Amount of urine cystine for type AA, BB, AAB/BBA, A and B were 1230.6, 1815.45, 1434, 3034.6 and 1968.8&#160;&#181;&#160;mol/day, respectively. No significant difference in the amount of urine cystine was observed between genotypes (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>B, Table <xref rid="Tab4" ref-type="table">4</xref>). Age of onset for type AA, BB, AAB/BBA, and B were 13, 16, 27, and 13.5, respectively. No significant difference in the age of onset was observed between genotypes (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>C).</p></sec><sec id="Sec8"><title>Genotype&#8211;phenotype association based on p.(Pro482Leu) variant in <italic toggle="yes">SLC7A9</italic></title><p id="Par14">Regarding p.(Pro482Leu) variant in <italic toggle="yes">SLC7A9</italic>, 43 patients (42.6%) had homozygote variants, 26 (25.7%) patients had compound heterozygote variants, four patients (4.0%) had single heterozygote variant and 28 patients (27.7%) had no p.(Pro482Leu) variant (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>A). Amount of urine cystine for the patients of homozygote P482L variant, compound heterozygote p.(Pro482Leu) variant, single p.(Pro482Leu) variant and no p.(Pro482Leu) variant were 1705.2, 2359.3, 1280.8, and 1483.7&#160;&#181;&#160;mol/day, respectively. No significant difference in the amount of urine cystine was observed between p.(Pro482Leu) based genotypes (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>B, Table <xref rid="Tab4" ref-type="table">4</xref>). Age of onset for type p.(Pro482Leu) homo, compound p.(Pro482Leu) hetero, none p.(Pro482Leu) were 20,10 and 16, respectively. No significant difference in the age of onset was observed based on the p.(Pro482Leu) variant classification (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>C).<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Distribution of p.(Pro482Leu) variant. Distribution of p.(Pro482Leu) variant represented predominance of homozygote variant (n&#8201;=&#8201;43) followed by compound heterozygote variant (n&#8201;=&#8201;26) (<bold>A</bold>). Urine cystine based on p.(Pro482Leu) variant (<bold>B</bold>). Age of onset based on P482L variant (<bold>C</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="41598_2025_14240_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec9"><title>Variants in exon&#8211;intron boundary</title><p id="Par15">Overall, six exon&#8211;intron boundary variants were identified in six patients (Table <xref rid="Tab5" ref-type="table">5</xref>). Among two patients without any variant in exon, one patient had homozygote variant (c.1224&#8201;+&#8201;3A&#8201;&gt;&#8201;C) (classified as type BB), and the other patient had heterozygote variant (c.1399&#8201;+&#8201;4_1399&#8201;+&#8201;7delAGTA) in exon&#8211;intron boundary (classified as type B) (Table <xref rid="Tab5" ref-type="table">5</xref>). All six patients who possessed exon&#8211;intron boundary variant resulted in the reclassification of the genotype (Table <xref rid="Tab5" ref-type="table">5</xref>). The patients who had intron&#8211;exon boundary variants showed a relatively higher amount of cystine (3214.8&#160;&#181;mol/day) compared to those of patients who had exon variants (1705.4&#160;&#181;mol/day) (Table <xref rid="Tab6" ref-type="table">6</xref>).<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>List of cases with Exon&#8211;Intron boundary variants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="2" rowspan="1"><italic toggle="yes">SLC3A1</italic></th><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="2" rowspan="1"><italic toggle="yes">SLC7A9</italic></th><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="2" rowspan="1">Genotype</th></tr><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="2" rowspan="1">Variants</th><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="2" rowspan="1">Variants</th><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Exon only</th><th align="left" colspan="1" rowspan="1">Exon/Exon&#8211;Intron boundary</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">p.(Thr204fs) c.611_612delCA (hetero)</td><td align="left" colspan="1" rowspan="1">c.873&#8201;+&#8201;2dupT (hetero)*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Type B</td><td align="left" colspan="1" rowspan="1">Type BB</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">c.1224&#8201;+&#8201;3A&#8201;&gt;&#8201;C (homo)*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">No mutation</td><td align="left" colspan="1" rowspan="1">Type BB</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="2" rowspan="1">c.1399&#8201;+&#8201;4_1399&#8201;+&#8201;7delAGTA (hetero)*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">No mutation</td><td align="left" colspan="1" rowspan="1">Type B</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">p.(Tyr371Ter)(hetero)c.1113C&#8201;&gt;&#8201;A</td><td align="left" colspan="1" rowspan="1">c.1500&#8201;+&#8201;1G&#8201;&gt;&#8201;A (hetero)*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Type A</td><td align="left" colspan="1" rowspan="1">Type AA</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">p.(Pro441Arg)(hetero)c.1323C&#8201;&gt;&#8201;G</td><td align="left" colspan="1" rowspan="1">c.1617&#8201;+&#8201;1_1617&#8201;+&#8201;2dupGT (hetero)*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Type A</td><td align="left" colspan="1" rowspan="1">Type AA</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">p.(Pro482Leu)(hetero)c.1445C&#8201;&gt;&#8201;T</td><td align="left" colspan="1" rowspan="1">c.1074&#8201;+&#8201;1G&#8201;&gt;&#8201;A (hetero)*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Type B</td><td align="left" colspan="1" rowspan="1">Type BB</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="8" rowspan="1">* Exon&#8211;Intron boundary (Splice site) variant</td></tr></tbody></table></table-wrap><table-wrap id="Tab6" position="float" orientation="portrait"><label>Table 6</label><caption><p>Urine amino acid concentration based on Exon/Exon&#8211;intron boundary variants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="8" rowspan="1"><italic toggle="yes">Urine Amino acids: &#181;mol/day</italic></th></tr><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Cystine</th><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Ornithine</th><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Lysine</th><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Arginine</th><th align="left" colspan="1" rowspan="1"/></tr><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Median</th><th align="left" colspan="1" rowspan="1">Range</th><th align="left" colspan="1" rowspan="1">Median</th><th align="left" colspan="1" rowspan="1">Range</th><th align="left" colspan="1" rowspan="1">Median</th><th align="left" colspan="1" rowspan="1">Range</th><th align="left" colspan="1" rowspan="1">Median</th><th align="left" colspan="1" rowspan="1">Range</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Exon variant</td><td align="left" colspan="1" rowspan="1">1705.4</td><td align="left" colspan="1" rowspan="1">(184.6&#8211;5303.4)</td><td align="left" colspan="1" rowspan="1">2044.3</td><td align="left" colspan="1" rowspan="1">(205.2&#8211;7471.7)</td><td align="left" colspan="1" rowspan="1">8538.6</td><td align="left" colspan="1" rowspan="1">(536.9&#8211;36961.6)</td><td align="left" colspan="1" rowspan="1">3512.6</td><td align="left" colspan="1" rowspan="1">(96.3&#8211;12096)</td></tr><tr><td align="left" colspan="1" rowspan="1">Exon&#8211;intron boundary variant</td><td align="left" colspan="1" rowspan="1">3214.8</td><td align="left" colspan="1" rowspan="1">(1025.6&#8211;4094.2)</td><td align="left" colspan="1" rowspan="1">2732.3</td><td align="left" colspan="1" rowspan="1">(845.4&#8211;3922.7)</td><td align="left" colspan="1" rowspan="1">9134.9</td><td align="left" colspan="1" rowspan="1">(2411.5&#8211;10211.1)</td><td align="left" colspan="1" rowspan="1">1169.5</td><td align="left" colspan="1" rowspan="1">(555.9&#8211;4362.4)</td></tr></tbody></table></table-wrap></p><p id="Par16">In the case with homozygote c.1224&#8201;+&#8201;3A&#8201;&gt;&#8201;C variant, we have studied the mRNA expression of the <italic toggle="yes">SLC3A1</italic> and <italic toggle="yes">SLC7A9</italic>. The male patient with the family history of urinary stone had first symptoms of kidney stone at the age of 3. At the age of 28, the patient consulted the hospital due to left back pain. Computed tomographic scanning showed left staghorn calculus (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>A). Based on genomic analysis, the location of the variant was three nucleotides at the boundary of exon 11 (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>B). No variant in exon was identified. The patient had a high amount of urinary cystine (3311.6&#160;&#181;mol/day) along with a high amount of lysine, ornithine, and arginine (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>C). mRNA expression of the renal tissue showed a significant loss of <italic toggle="yes">SLC7A9</italic> expression compared to that of <italic toggle="yes">SLC3A1</italic> by RNA sequence (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>D). Based on the genotype cover exon and exon&#8211;intron boundary, the case that did not fit the genotype of autosomal recessive inheritance reduced to 9 cases from 14 cases out of 101 cases (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>E).<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>The case with homozygote exon&#8211;intron boundary variant. The CT image of the patient with left staghorn calculus (<bold>A</bold>). The case possessed c.1224&#8201;+&#8201;3A&#8201;&gt;&#8201;C homozygote variant in <italic toggle="yes">SLC7A9</italic>, which was located 3 bases into the intron from the exon-intron boundary (<bold>B</bold>). 24&#160;h urine amino acids of the patient (<bold>C</bold>). mRNA expression of the <italic toggle="yes">SCL3A1</italic> and <italic toggle="yes">SLC7A9</italic> genes based on the RNA sequence (<bold>D</bold>). FPKM represent RNA expression based on the number of fragments per kilobase of exon per million reads mapped. Based on the genotype cover exon and exon-intron boundary, the cases that do not fit into the autosomal recessive inheritance category reduced to 9 cases from 14 cases (<bold>E</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="41598_2025_14240_Fig5_HTML.jpg"/></fig></p></sec><sec id="Sec10"><title>Cases with a single variant</title><p id="Par17">Eight cases had only a single variant: seven in the exon region and one in the intron region. The median cystine concentration of the case with a single variant was 2501.7&#160;&#181;mol/day, which was above the median cystine concentration of whole cohort of 1745.7&#160;&#181;mol/day (Table S1).</p></sec><sec id="Sec11"><title>Roots of cystinuria patients</title><p id="Par18">We also study the origin of cystinuria patients. 77% of patients are from the Kanto area (central region), where Tokyo and Chiba prefectures are located. 8% of patients are from the Kansai area (middle west), where Osaka prefecture is located. 7% of patients are from the Tokai area (middle south), where Aichi prefecture is located. No patient from the Tohoku area (north) was identified in this study (Fig. <xref rid="MOESM1" ref-type="media">S1A</xref>). Related to the percent of p.(Pro482Leu) variant, 100% of patients possessed p.(Pro482Leu) variant from Hokuriku (middle north), Kyusyu (far west), and Shikoku area (south west island). 76% and 57% of patients possessed p.(Pro482Leu) variant from Kanto (Tokyo and surrounding area) and Tokai area (middle south), respectively, while 37.5% from the Kansai area (middle west). No patients from Hokkaido area (northern island) possessed p.(Pro482Leu) variant (Fig. <xref rid="MOESM1" ref-type="media">S1 6B</xref>).</p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par19">Cystinuria is the most common genetic related kidney stones that is responsible for 1% of kidney stones<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>. Since Japan is geographically isolated by the ocean and even conducted a national isolation policy in the past during the Edo era (in 1636&#8211;1854), the development of genetic characteristics can be different from the rest of the countries.</p><p id="Par20">Among Japanese cystinuria patients, 73 out of 101 patients possessed p.(Pro482Leu) variant. Based on the common genome database (genome AD <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://gnomad.broadinstitute.org/">https://gnomad.broadinstitute.org/</ext-link>), the distribution of p.(Pro482Leu) variant in <italic toggle="yes">SLC7A9</italic> among the global population is rare. p.(Pro482Leu) was not found in African, Latino, Ashkenazi Jewish, and European (Finish). Even for Asians, the allele frequency of p.(Pro482Leu) for south Asian and East Asian are 0.00006533 and 0.00005012, respectively. Among the previous Asian study of cystinuria, only 1 out of 8 cystinuria patients possessed p.(Pro482Leu) (heterozygote) in south Korean<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>, while no p.(Pro482Leu) was identified in Chinese<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. The p.(Pro482Leu) variant is located at the carboxyl terminus (C-terminus) end of b<sup>0,+</sup>AT, which causes severe transporter defect comparative to those of frameshift and stop codon variant<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. Our previous study identified the &#8220;VPP&#8221; motif at the carboxyl terminus of b<sup>0,+</sup>AT regulate the ER-Golgi trafficking and thus control glycosylation of rBAT protein<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. The last P in the &#8220;VPP&#8221; motif represented the location of p.(Pro482Leu) variant.</p><p id="Par21">Related to the genotype classification, the distribution of type BB was found in 76%, while type AA was only found in 12% of patients in the current Japanese study. In the UK study, type AA is dominant (36%), followed by type BB (26%). In the Chinese Study, 37.5% (3 out of 8) were type AA, and 25% (2 out of 8) were type BB. In a Korean study, 50% (4 out of 8) of patients were type AA, and only one patient (12.5%) was type BB. These data indicated the global trends of <italic toggle="yes">SLC3A1</italic> variant (type AA) in European and even Asian cystinuria patients. Thus, the predominance of <italic toggle="yes">SLC7A9</italic> variant (type BB) genotype found in Japanese cystinuria patients seems to be unique characteristics. Beside <italic toggle="yes">SLC3A1</italic> and <italic toggle="yes">SLC7A9</italic>, novel cystine transporter, sodium-independent aspartate/glutamate transporter 1 (AGT1, SLC7A13) was identified<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. However, so far, no pathogenic variants were reported<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>.</p><p id="Par22">In a UK study, patients who have a variant in <italic toggle="yes">SLC3A1</italic> (type A or AA) demonstrated a significantly lower level of lysine, arginine, and ornithine, but not cystine compared to those of other patients<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. Another study from the UK presented no difference in the clinical parameter between type AA and type BB. Furthermore, patients with a single mutated allele demonstrated similar disease severity compared to those of 2 mutated alleles<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. In the current study, no difference in the severity of cystinuria, such as urine cystine and age of onset, were observed based on the gene of variant (between <italic toggle="yes">SLC3A1</italic> and <italic toggle="yes">SLC7A9</italic>), genotype (between type AA and type BB), and the number of mutated alleles. The difference in the clinical phenotype may be derived from a wide difference in the basal genome variants, in which we found 13 novel variants in <italic toggle="yes">SLC3A1</italic> and 12 novel variants in <italic toggle="yes">SLC7A9</italic> (total of 25 novel variants).</p><p id="Par23">It has been a missing piece of cystinuria that up to 30% of patients did not fit into autosomal recessive inheritance category by exon variants<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>, which may be partially explained by variants in intron. In the current study, six exon&#8211;intron variants were identified, which resulted in the reclassification of the genotype. In the case with homozygote c.1224&#8201;+&#8201;3A&#8201;&gt;&#8201;C variant in <italic toggle="yes">SLC7A9</italic>, almost complete loss of <italic toggle="yes">SLC7A9</italic> mRNA expression was observed by the exon&#8211;intron boundary variant. This data is, we believe, the first direct evidence of the significance of exon&#8211;intron boundary variant, which resulted in the loss of the transporter expression. Based on the genotype cover exon and exon&#8211;intron boundary, the cases that do not fit into the autosomal recessive inheritance category reduced to 9 cases from 14 cases.</p><p id="Par24">When looking at the origin of cystinuria patients among the Japanese population, most of the patients were found from the middle (Kanto and Tokai) and west (Kansai) side of Japan. No patient was found on the northeast side of Japan (Tohoku Area) except one patient in Hokkaido (Northern Island). The current Japanese population is proposed to be the result of admixture between the early migrants (Jomon people) and later migrants (Yayoi people). Jomon people lived in the Northern and Southern parts of Japan, while Yayoi people lived in the central part of Japan. Few cystinuria patients from the northeast side of Japan may indicate Japanese cystinuria patients&#8217; roots may be derived from Yayoi people, rather than Jomon people<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. We are currently studying the association of Japanese cystinuria patients with Yayoi or Jomon people based on the genome-wide SNP data, especially related to the p.(Pro482Leu) variant in <italic toggle="yes">SLC7A9</italic>.</p><p id="Par25">The current manuscript contained several limitations. First, the data was obtained from Chiba university hospital with the collaboration with the hospitals from 15 different prefectures ranged from the northern part (Hokkaido) and the west side (Kyusyu) of Japan. Although data is obtained from a wide range of locations, our data missed some of the location in Japan. Second, the data is obtained in a retrospective manner. Third, presence of splicing error induced by the exon&#8211;intron boundary variants has not fully been validated except for one case presented. We are currently assessing the presence of splicing error due to the variants in exon&#8211;intron boundaries by in vitro transcription. Fourth, copy number variant (CNV) analysis was not performed in this study. We are currently preparing CNV analysis in Japanese cohort, thus we will report the result in the following paper.</p><p id="Par26">In conclusion, the current manuscript described the genomic and clinical signature of Japanese cystinuria patients, which is distinct from not only European cystinuria patients but also from Asian cystinuria patients. Genotype classification may be updated based on not only exon but also exon&#8211;intron boundary variants.</p></sec><sec id="Sec13"><title>Methods</title><sec id="Sec14"><title>Patient information</title><p id="Par27">Patients recruited to this study all had a clinical diagnosis of cystinuria on the basis of clinical diagnosis of cystine stones from the southwest to northeast part of Japan between 2000 and 2020. Detailed clinical data were retrospectively collected. Demographics (age, sex and ethnicity) and age at the first stone events, treatment history, and urine biochemistry were collected.</p></sec><sec id="Sec15"><title>Definition of urine amino acids</title><p id="Par28">Cystine, lysine, arginine, and ornithine were measured by twenty-four hours urine sample. The amount of urine amino acids was determined by high performance liquid chromatography (HPLC) at SRL, Inc. (Hachioji, Tokyo, Japan).</p></sec><sec id="Sec16"><title>Statistical analysis</title><p id="Par29">Mann&#8211;Whitney&#8217;s U test, ANOVA analysis, and the &#967;2 test were used for comparisons of two or three groups. Spearman&#8217;s rank correlation coefficient was used to analyze the relationship between the two groups. Statistical computations were performed using JMP 11.0.0 (SAS Institute, NC, USA). <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 was considered significant.</p></sec><sec id="Sec17"><title>Genetic analysis</title><p id="Par30">Genomic DNA was extracted from whole blood using the Blood &amp; Cell Culture DNA Midi Kit (Qiagen, Hilden, Germany). Genetic variants of <italic toggle="yes">SLC3A1</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000341.3">NM_000341.3</ext-link>) and <italic toggle="yes">SLC7A9</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001126335.1">NM_001126335.1</ext-link>) were analyzed by next-generation sequence of the protein-coding exons and their intron boundaries essentially as described previously<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. In brief, libraries for the next generation sequence were made by a KAPA Hyper Plus Library Kit. Hybridization capture was made by predesigned hybridization capture probes for <italic toggle="yes">SLC3A1</italic> and <italic toggle="yes">SLC7A9</italic> purchased from IDT. The libraries were sequenced on an Illumina NextSeq500. Variant calling was done using GATKv4 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://gatk.broadinstitute.org/hc/en-us">https://gatk.broadinstitute.org/hc/en-us</ext-link>). The variants thus detected by the next-generation sequencing were again confirmed by Sanger sequencing. The next-generation sequencing analysis was conducted at the Kazusa DNA Research Institute (Kisarazu, Chiba, Japan). Unreported (novel) variant was defined as the variant not reported on the previous publication. These gene variants are described with reference to the sequence of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000341.3">NM_000341.3</ext-link> for the <italic toggle="yes">SLC3A1</italic> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001126335.1">NM_001126335.1</ext-link> for the <italic toggle="yes">SLC7A9</italic>.</p></sec><sec id="Sec18"><title>RNA sequencing</title><p id="Par31">The kidney tissue was obtained by biopsy. Total RNA from kidney biopsy sample was extracted using the RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA sequencing libraries were prepared using a SureSelect Strand-Specific RNA Library Prep Kit (Agilent Technologies, Inc., Santa Clara, CA, USA). Sequencing was performed on a HiSeq 2500 system (Illumina, Santiago, CA, USA) in a 50-base single-end mode. TopHat (version 2.1.0; with default parameters) was used to map to the human reference genome (hg38). Then, gene expression levels were quantified using Cufflinks version 2.2.1; with default parameters) and are expressed as the number of fragments per kilobase of exon per million reads mapped (FPKM).</p></sec></sec><sec id="Sec19" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_14240_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Information 1.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_14240_MOESM2_ESM.pptx" position="float" orientation="portrait"><caption><p>Supplementary Information 2.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_14240_MOESM3_ESM.xlsx" position="float" orientation="portrait"><caption><p>Supplementary Information 3.</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-025-14240-4.</p></sec><ack><title>Acknowledgement</title><p>The authors thank Osamu Ohara (Kazusa DNA Research Institute, Kisarazu, Japan) for the NGS analysis and RNA sequence. The author also thanks, Natsuko Kusama, Masako Takahashi, Hisayo Karahi, Keiko Yamazaki (Experimental assistant, Chiba University) for their support of this study.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>YN and SS conceived and designed the experiments. JR, SS, ST, NS, and CH analyzed the data. AC, KW, MN, MS, MF, TU, TY, YK, YS, YY, KA, KW, YI, YI(Yusuke Imamura), YI(Yoshikatsu Kanai), NA, and TI supervised the study. SH and KT provided the samples. XZ supports the database registry to the DDBJ Japanese Genotype&#8211;phenotype Archive.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The present work was supported by 5th research grant from Japanese Society on Urolithiasis Research to S. Sakamoto, the Japan Agency for Medical Research and Development, the Initiative on Rare and Undiagnosed Diseases (IRUD) to T. Ichikawa and the Japan Agency for Medical Research and Development (AMED) (JP21ek0109549) to T. Ichikawa.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets generated and analysed during the current study are available in the NBDC Human Database with JGA accession number Study: JGAS000817, Dataset: JGAD000959.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par32">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethical approval and Consent to participate</title><p id="Par33">The present study was conducted in accordance with ethical standards that promote and ensure respect and integrity for all human subjects and the Declaration of Helsinki. This study was approved by the institutional review board of Chiba University Hospital (approval number 1050), Nagoya City University Hospital (approval number of 70-19-0018) and other participated hospitals and written informed consent was obtained from all patients.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ito</surname><given-names>H</given-names></name><etal/></person-group><article-title>The incidence of cystinuria in Japan</article-title><source>J. Urol.</source><year>1983</year><volume>129</volume><fpage>1012</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1016/s0022-5347(17)52514-8</pub-id><pub-id pub-id-type="pmid">6406687</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Ito, H. et al. The incidence of cystinuria in Japan. <italic toggle="yes">J. Urol.</italic><bold>129</bold>, 1012&#8211;1014. 10.1016/s0022-5347(17)52514-8 (1983).<pub-id pub-id-type="pmid">6406687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0022-5347(17)52514-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chillaron</surname><given-names>J</given-names></name><etal/></person-group><article-title>Pathophysiology and treatment of cystinuria</article-title><source>Nat. Rev. Nephrol.</source><year>2010</year><volume>6</volume><fpage>424</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2010.69</pub-id><pub-id pub-id-type="pmid">20517292</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Chillaron, J. et al. Pathophysiology and treatment of cystinuria. <italic toggle="yes">Nat. Rev. Nephrol.</italic><bold>6</bold>, 424&#8211;434. 10.1038/nrneph.2010.69 (2010).<pub-id pub-id-type="pmid">20517292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneph.2010.69</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harnevik</surname><given-names>L</given-names></name><name name-style="western"><surname>Fjellstedt</surname><given-names>E</given-names></name><name name-style="western"><surname>Molbaek</surname><given-names>A</given-names></name><name name-style="western"><surname>Denneberg</surname><given-names>T</given-names></name><name name-style="western"><surname>Soderkvist</surname><given-names>P</given-names></name></person-group><article-title>Mutation analysis of SLC7A9 in cystinuria patients in Sweden</article-title><source>Genet. Test.</source><year>2003</year><volume>7</volume><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1089/109065703321560886</pub-id><pub-id pub-id-type="pmid">12820697</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Harnevik, L., Fjellstedt, E., Molbaek, A., Denneberg, T. &amp; Soderkvist, P. Mutation analysis of SLC7A9 in cystinuria patients in Sweden. <italic toggle="yes">Genet. Test.</italic><bold>7</bold>, 13&#8211;20. 10.1089/109065703321560886 (2003).<pub-id pub-id-type="pmid">12820697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/109065703321560886</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bertran</surname><given-names>J</given-names></name><etal/></person-group><article-title>Expression cloning of a human renal cDNA that induces high affinity transport of L-cystine shared with dibasic amino acids in Xenopus oocytes</article-title><source>J. Biol. Chem.</source><year>1993</year><volume>268</volume><fpage>14842</fpage><lpage>14849</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)82410-3</pub-id><pub-id pub-id-type="pmid">7686906</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Bertran, J. et al. Expression cloning of a human renal cDNA that induces high affinity transport of L-cystine shared with dibasic amino acids in Xenopus oocytes. <italic toggle="yes">J. Biol. Chem.</italic><bold>268</bold>, 14842&#8211;14849 (1993).<pub-id pub-id-type="pmid">7686906</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chairoungdua</surname><given-names>A</given-names></name><etal/></person-group><article-title>Identification of an amino acid transporter associated with the cystinuria-related type II membrane glycoprotein</article-title><source>J. Biol. Chem.</source><year>1999</year><volume>274</volume><fpage>28845</fpage><lpage>28848</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.41.28845</pub-id><pub-id pub-id-type="pmid">10506124</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Chairoungdua, A. et al. Identification of an amino acid transporter associated with the cystinuria-related type II membrane glycoprotein. <italic toggle="yes">J. Biol. Chem.</italic><bold>274</bold>, 28845&#8211;28848. 10.1074/jbc.274.41.28845 (1999).<pub-id pub-id-type="pmid">10506124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.274.41.28845</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feliubadalo</surname><given-names>L</given-names></name><etal/></person-group><article-title>Non-type I cystinuria caused by mutations in SLC7A9, encoding a subunit (bo,+AT) of rBAT</article-title><source>Nat. Genet.</source><year>1999</year><volume>23</volume><fpage>52</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/12652</pub-id><pub-id pub-id-type="pmid">10471498</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Feliubadalo, L. et al. Non-type I cystinuria caused by mutations in SLC7A9, encoding a subunit (bo,+AT) of rBAT. <italic toggle="yes">Nat. Genet.</italic><bold>23</bold>, 52&#8211;57. 10.1038/12652 (1999).<pub-id pub-id-type="pmid">10471498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/12652</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Segawa</surname><given-names>H</given-names></name><etal/></person-group><article-title>Identification and functional characterization of a Na+-independent neutral amino acid transporter with broad substrate selectivity</article-title><source>J. Biol. Chem.</source><year>1999</year><volume>274</volume><fpage>19745</fpage><lpage>19751</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.28.19745</pub-id><pub-id pub-id-type="pmid">10391916</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Segawa, H. et al. Identification and functional characterization of a Na+-independent neutral amino acid transporter with broad substrate selectivity. <italic toggle="yes">J. Biol. Chem.</italic><bold>274</bold>, 19745&#8211;19751. 10.1074/jbc.274.28.19745 (1999).<pub-id pub-id-type="pmid">10391916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.274.28.19745</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egoshi</surname><given-names>KI</given-names></name><name name-style="western"><surname>Akakura</surname><given-names>K</given-names></name><name name-style="western"><surname>Kodama</surname><given-names>T</given-names></name><name name-style="western"><surname>Ito</surname><given-names>H</given-names></name></person-group><article-title>Identification of five novel SLC3A1 (rBAT) gene mutations in Japanese cystinuria</article-title><source>Kidney Int.</source><year>2000</year><volume>57</volume><fpage>25</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2000.00821.x</pub-id><pub-id pub-id-type="pmid">10620184</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Egoshi, K. I., Akakura, K., Kodama, T. &amp; Ito, H. Identification of five novel SLC3A1 (rBAT) gene mutations in Japanese cystinuria. <italic toggle="yes">Kidney Int.</italic><bold>57</bold>, 25&#8211;32. 10.1046/j.1523-1755.2000.00821.x (2000).<pub-id pub-id-type="pmid">10620184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1523-1755.2000.00821.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakamoto</surname><given-names>S</given-names></name><etal/></person-group><article-title>A novel role of the C-terminus of b 0,+ AT in the ER-Golgi trafficking of the rBAT-b 0,+ AT heterodimeric amino acid transporter</article-title><source>Biochem. J.</source><year>2009</year><volume>417</volume><fpage>441</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1042/BJ20081798</pub-id><pub-id pub-id-type="pmid">19000035</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Sakamoto, S. et al. A novel role of the C-terminus of b 0,+ AT in the ER-Golgi trafficking of the rBAT-b 0,+ AT heterodimeric amino acid transporter. <italic toggle="yes">Biochem. J.</italic><bold>417</bold>, 441&#8211;448. 10.1042/BJ20081798 (2009).<pub-id pub-id-type="pmid">19000035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BJ20081798</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dello Strologo</surname><given-names>L</given-names></name><etal/></person-group><article-title>Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: A need for a new classification</article-title><source>J. Am. Soc. Nephrol.</source><year>2002</year><volume>13</volume><fpage>2547</fpage><lpage>2553</lpage><pub-id pub-id-type="doi">10.1097/01.asn.0000029586.17680.e5</pub-id><pub-id pub-id-type="pmid">12239244</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Dello Strologo, L. et al. Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: A need for a new classification. <italic toggle="yes">J. Am. Soc. Nephrol.</italic><bold>13</bold>, 2547&#8211;2553. 10.1097/01.asn.0000029586.17680.e5 (2002).<pub-id pub-id-type="pmid">12239244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.asn.0000029586.17680.e5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhodes</surname><given-names>HL</given-names></name><etal/></person-group><article-title>Clinical and genetic analysis of patients with cystinuria in the United Kingdom</article-title><source>Clin. J. Am. Soc. Nephrol.</source><year>2015</year><volume>10</volume><fpage>1235</fpage><lpage>1245</lpage><pub-id pub-id-type="doi">10.2215/CJN.10981114</pub-id><pub-id pub-id-type="pmid">25964309</pub-id><pub-id pub-id-type="pmcid">PMC4491297</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Rhodes, H. L. et al. Clinical and genetic analysis of patients with cystinuria in the United Kingdom. <italic toggle="yes">Clin. J. Am. Soc. Nephrol.</italic><bold>10</bold>, 1235&#8211;1245. 10.2215/CJN.10981114 (2015).<pub-id pub-id-type="pmid">25964309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.10981114</pub-id><pub-id pub-id-type="pmcid">PMC4491297</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>KA</given-names></name><etal/></person-group><article-title>The genetic diversity of cystinuria in a UK population of patients</article-title><source>BJU Int.</source><year>2015</year><volume>116</volume><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1111/bju.12894</pub-id><pub-id pub-id-type="pmid">25109415</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Wong, K. A. et al. The genetic diversity of cystinuria in a UK population of patients. <italic toggle="yes">BJU Int.</italic><bold>116</bold>, 109&#8211;116. 10.1111/bju.12894 (2015).<pub-id pub-id-type="pmid">25109415</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bju.12894</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shigeta</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A novel missense mutation of SLC7A9 frequent in Japanese cystinuria cases affecting the C-terminus of the transporter</article-title><source>Kidney Int.</source><year>2006</year><volume>69</volume><fpage>1198</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5000241</pub-id><pub-id pub-id-type="pmid">16609684</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Shigeta, Y. et al. A novel missense mutation of SLC7A9 frequent in Japanese cystinuria cases affecting the C-terminus of the transporter. <italic toggle="yes">Kidney Int.</italic><bold>69</bold>, 1198&#8211;1206. 10.1038/sj.ki.5000241 (2006).<pub-id pub-id-type="pmid">16609684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.ki.5000241</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Pediatric cystinuria patient with novel mutation in SLC3A1</article-title><source>Glob. Pediatr. Health</source><year>2019</year><volume>6</volume><fpage>2333794X19862441</fpage><pub-id pub-id-type="doi">10.1177/2333794X19862441</pub-id><pub-id pub-id-type="pmid">31367653</pub-id><pub-id pub-id-type="pmcid">PMC6643165</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Watanabe, Y. et al. Pediatric cystinuria patient with novel mutation in SLC3A1. <italic toggle="yes">Glob. Pediatr. Health</italic><bold>6</bold>, 2333794X19862441. 10.1177/2333794X19862441 (2019).<pub-id pub-id-type="pmid">31367653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2333794X19862441</pub-id><pub-id pub-id-type="pmcid">PMC6643165</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okada</surname><given-names>T</given-names></name><etal/></person-group><article-title>Efficacy of transurethral cystolithotripsy assisted by percutaneous evacuation and the benefit of genetic analysis in a pediatric cystinuria patient with a large bladder stone</article-title><source>Urol. Case Rep.</source><year>2021</year><volume>34</volume><fpage>101473</fpage><pub-id pub-id-type="doi">10.1016/j.eucr.2020.101473</pub-id><pub-id pub-id-type="pmid">33194555</pub-id><pub-id pub-id-type="pmcid">PMC7644569</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Okada, T. et al. Efficacy of transurethral cystolithotripsy assisted by percutaneous evacuation and the benefit of genetic analysis in a pediatric cystinuria patient with a large bladder stone. <italic toggle="yes">Urol. Case Rep.</italic><bold>34</bold>, 101473. 10.1016/j.eucr.2020.101473 (2021).<pub-id pub-id-type="pmid">33194555</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eucr.2020.101473</pub-id><pub-id pub-id-type="pmcid">PMC7644569</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abe</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Persistent leukocyturia was a clue to diagnosis of cystinuria in a female patient</article-title><source>Glob. Pediatr. Health</source><year>2014</year><volume>1</volume><fpage>2333794X14551275</fpage><pub-id pub-id-type="doi">10.1177/2333794X14551275</pub-id><pub-id pub-id-type="pmid">27335907</pub-id><pub-id pub-id-type="pmcid">PMC4804682</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Abe, Y. et al. Persistent leukocyturia was a clue to diagnosis of cystinuria in a female patient. <italic toggle="yes">Glob. Pediatr. Health</italic><bold>1</bold>, 2333794X14551275. 10.1177/2333794X14551275 (2014).<pub-id pub-id-type="pmid">27335907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2333794X14551275</pub-id><pub-id pub-id-type="pmcid">PMC4804682</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akakura</surname><given-names>K</given-names></name><etal/></person-group><article-title>The long-term outcome of cystinuria in Japan</article-title><source>Urol. Int.</source><year>1998</year><volume>61</volume><fpage>86</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1159/000030294</pub-id><pub-id pub-id-type="pmid">9873246</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Akakura, K. et al. The long-term outcome of cystinuria in Japan. <italic toggle="yes">Urol. Int.</italic><bold>61</bold>, 86&#8211;89. 10.1159/000030294 (1998).<pub-id pub-id-type="pmid">9873246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000030294</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>EH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YH</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SH</given-names></name></person-group><article-title>Non-type I cystinuria associated with mental retardation and ataxia in a Korean boy with a new missence mutation(G173R) in the SLC7A9 gene</article-title><source>J. Korean Med. Sci.</source><year>2010</year><volume>25</volume><fpage>172</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.3346/jkms.2010.25.1.172</pub-id><pub-id pub-id-type="pmid">20052367</pub-id><pub-id pub-id-type="pmcid">PMC2800027</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Lee, E. H., Kim, Y. H., Hwang, J. S. &amp; Kim, S. H. Non-type I cystinuria associated with mental retardation and ataxia in a Korean boy with a new missence mutation(G173R) in the SLC7A9 gene. <italic toggle="yes">J. Korean Med. Sci.</italic><bold>25</bold>, 172&#8211;175. 10.3346/jkms.2010.25.1.172 (2010).<pub-id pub-id-type="pmid">20052367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3346/jkms.2010.25.1.172</pub-id><pub-id pub-id-type="pmcid">PMC2800027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuen</surname><given-names>YP</given-names></name><etal/></person-group><article-title>Heterogeneous mutations in the SLC3A1 and SLC7A9 genes in Chinese patients with cystinuria</article-title><source>Kidney Int.</source><year>2006</year><volume>69</volume><fpage>123</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5000003</pub-id><pub-id pub-id-type="pmid">16374432</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Yuen, Y. P. et al. Heterogeneous mutations in the SLC3A1 and SLC7A9 genes in Chinese patients with cystinuria. <italic toggle="yes">Kidney Int.</italic><bold>69</bold>, 123&#8211;128. 10.1038/sj.ki.5000003 (2006).<pub-id pub-id-type="pmid">16374432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.ki.5000003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anna</surname><given-names>A</given-names></name><name name-style="western"><surname>Monika</surname><given-names>G</given-names></name></person-group><article-title>Splicing mutations in human genetic disorders: Examples, detection, and confirmation</article-title><source>J. Appl. Genet.</source><year>2018</year><volume>59</volume><fpage>253</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1007/s13353-018-0444-7</pub-id><pub-id pub-id-type="pmid">29680930</pub-id><pub-id pub-id-type="pmcid">PMC6060985</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Anna, A. &amp; Monika, G. Splicing mutations in human genetic disorders: Examples, detection, and confirmation. <italic toggle="yes">J. Appl. Genet.</italic><bold>59</bold>, 253&#8211;268. 10.1007/s13353-018-0444-7 (2018).<pub-id pub-id-type="pmid">29680930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13353-018-0444-7</pub-id><pub-id pub-id-type="pmcid">PMC6060985</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakamoto</surname><given-names>S</given-names></name><etal/></person-group><article-title>Chronological changes in epidemiological characteristics of lower urinary tract urolithiasis in Japan</article-title><source>Int. J. Urol.</source><year>2019</year><volume>26</volume><fpage>96</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1111/iju.13817</pub-id><pub-id pub-id-type="pmid">30308705</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Sakamoto, S. et al. Chronological changes in epidemiological characteristics of lower urinary tract urolithiasis in Japan. <italic toggle="yes">Int. J. Urol.</italic><bold>26</bold>, 96&#8211;101. 10.1111/iju.13817 (2019).<pub-id pub-id-type="pmid">30308705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/iju.13817</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakamoto</surname><given-names>S</given-names></name><etal/></person-group><article-title>Chronological changes in the epidemiological characteristics of upper urinary tract urolithiasis in Japan</article-title><source>Int. J. Urol.</source><year>2018</year><volume>25</volume><fpage>373</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1111/iju.13552</pub-id><pub-id pub-id-type="pmid">29648701</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Sakamoto, S. et al. Chronological changes in the epidemiological characteristics of upper urinary tract urolithiasis in Japan. <italic toggle="yes">Int. J. Urol.</italic><bold>25</bold>, 373&#8211;378. 10.1111/iju.13552 (2018).<pub-id pub-id-type="pmid">29648701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/iju.13552</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Genotype and phenotype analysis in pediatric patients with cystinuria</article-title><source>J. Korean Med. Sci.</source><year>2017</year><volume>32</volume><fpage>310</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.3346/jkms.2017.32.2.310</pub-id><pub-id pub-id-type="pmid">28049243</pub-id><pub-id pub-id-type="pmcid">PMC5219998</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Kim, J. H. et al. Genotype and phenotype analysis in pediatric patients with cystinuria. <italic toggle="yes">J. Korean Med. Sci.</italic><bold>32</bold>, 310&#8211;314. 10.3346/jkms.2017.32.2.310 (2017).<pub-id pub-id-type="pmid">28049243</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3346/jkms.2017.32.2.310</pub-id><pub-id pub-id-type="pmcid">PMC5219998</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagamori</surname><given-names>S</given-names></name><etal/></person-group><article-title>Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A1</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>775</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1073/pnas.1519959113</pub-id><pub-id pub-id-type="pmid">26739563</pub-id><pub-id pub-id-type="pmcid">PMC4725474</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Nagamori, S. et al. Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A1. <italic toggle="yes">Proc. Natl. Acad. Sci. USA</italic><bold>113</bold>, 775&#8211;780. 10.1073/pnas.1519959113 (2016).<pub-id pub-id-type="pmid">26739563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1519959113</pub-id><pub-id pub-id-type="pmcid">PMC4725474</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olschok</surname><given-names>K</given-names></name><name name-style="western"><surname>Vester</surname><given-names>U</given-names></name><name name-style="western"><surname>Lahme</surname><given-names>S</given-names></name><name name-style="western"><surname>Kurth</surname><given-names>I</given-names></name><name name-style="western"><surname>Eggermann</surname><given-names>T</given-names></name></person-group><article-title>No evidence for point mutations in the novel renal cystine transporter AGT1/SLC7A13 contributing to the etiology of cystinuria</article-title><source>BMC Nephrol.</source><year>2018</year><volume>19</volume><fpage>278</fpage><pub-id pub-id-type="doi">10.1186/s12882-018-1080-5</pub-id><pub-id pub-id-type="pmid">30342472</pub-id><pub-id pub-id-type="pmcid">PMC6196009</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Olschok, K., Vester, U., Lahme, S., Kurth, I. &amp; Eggermann, T. No evidence for point mutations in the novel renal cystine transporter AGT1/SLC7A13 contributing to the etiology of cystinuria. <italic toggle="yes">BMC Nephrol.</italic><bold>19</bold>, 278. 10.1186/s12882-018-1080-5 (2018).<pub-id pub-id-type="pmid">30342472</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12882-018-1080-5</pub-id><pub-id pub-id-type="pmcid">PMC6196009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jinam</surname><given-names>TA</given-names></name><etal/></person-group><article-title>Unique characteristics of the Ainu population in Northern Japan</article-title><source>J. Hum. Genet.</source><year>2015</year><volume>60</volume><fpage>565</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1038/jhg.2015.79</pub-id><pub-id pub-id-type="pmid">26178428</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Jinam, T. A. et al. Unique characteristics of the Ainu population in Northern Japan. <italic toggle="yes">J. Hum. Genet.</italic><bold>60</bold>, 565&#8211;571. 10.1038/jhg.2015.79 (2015).<pub-id pub-id-type="pmid">26178428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jhg.2015.79</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujiki</surname><given-names>R</given-names></name><etal/></person-group><article-title>Assessing the accuracy of variant detection in cost-effective gene panel testing by next-generation sequencing</article-title><source>J. Mol. Diagn.</source><year>2018</year><volume>20</volume><fpage>572</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1016/j.jmoldx.2018.04.004</pub-id><pub-id pub-id-type="pmid">29953964</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Fujiki, R. et al. Assessing the accuracy of variant detection in cost-effective gene panel testing by next-generation sequencing. <italic toggle="yes">J. Mol. Diagn.</italic><bold>20</bold>, 572&#8211;582. 10.1016/j.jmoldx.2018.04.004 (2018).<pub-id pub-id-type="pmid">29953964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jmoldx.2018.04.004</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>